AFM
ATHE

Anson Funds Management’s Alterity Therapeutics ATHE Stock Holding History

Anson Funds Management’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,811
Closed -$178K – 45
2014
Q4 		$178K Buy
+1,811
New +$196K 0.21% 55

Other funds holding ATHE

GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CAM
Columbia Asset Management Ann Arbor, Michigan $525M AUM 21.5% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $1.87B AUM 29.51% 1-Year Est. Return
NCCM
Nine Chapters Capital Management Short Hills, New Jersey $45.4M AUM 14.43% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Anson Funds Management's ATHE Position: Q1 2015 in Review

Anson Funds Management sold out of Alterity Therapeutics (ATHE) in Q1 2015, closing a stake of 1,811 shares — an estimated $178K sold.

Anson Funds Management first reported a position in ATHE in Q4 2014 and held it in 1 quarter. The position peaked at $178K in Q4 2014. 21 funds tracked by Wall St. Rank hold ATHE as of Q1 2015.

  • Anson Funds Management reported no remaining Alterity Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Anson Funds Management sold 1,811 Alterity Therapeutics shares in Q1 2015, an estimated $178K.
  • Anson Funds Management first reported a position in Alterity Therapeutics in Q4 2014 and held it in 1 quarter.
  • Anson Funds Management's Alterity Therapeutics position peaked at $178K in Q4 2014.
  • 21 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2015.

Based on Anson Funds Management's 13F filing for Q1 2015, filed 15 May 2015.